February 2024- Tempus, a leader in artificial intelligence and precision medicine, announced that David R. Epstein has joined its Board of Directors. David will serve as an advisor to Tempus and its leadership team, applying his vast experience in biopharma to guide Tempus as it leverages data and AI to support novel therapeutic research and development.

David most recently served as Seagen’s Chief Executive Officer and member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and completed an acquisition by Pfizer in December of 2023. Prior to Seagen, David was Executive Partner at Flagship Pioneering, a developer of bioplatform companies. He also served as Novartis Pharmaceuticals’ Chief Executive Officer, as well as led the company’s Oncology and Molecular Diagnostic units. Throughout his career, David has led the development and commercialization of over 30 new molecular entities.

“We are honored to have David join our board during a time in which we are expanding our strategic collaborations with the top biotech and pharmaceutical companies,” said Eric Lefkofsky, Founder and CEO of Tempus. “Tempus has always been committed to using AI to not only advance clinical decisions but also research. David’s expertise in leading the development and commercialization of transformative treatments will be of great support as we seek new and innovative ways to partner with biopharma.”

“Tempus has developed a distinct set of solutions that has real potential to revolutionize cancer care,” David said. “I look forward to working with the leadership team in developing those offerings to provide even more value to the company, its partners, and ultimately patients.”